Appendix

Table A1. Patient profiles from four clinics

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Baseline characteristics** | Community wound clinic 1 (n=41) | | | Specialist wound clinic (n=11) | | | Hospital outpatient clinic (n=18) | | | Community wound clinic 2 (n=10) | | |  |
| **Continuous variables** | **N** | **mean** | **SD** | **N** | **mean** | **SD** | **N** | **mean** | **SD** | **N** | **mean** | **SD** | ANOVA test |
| Age | 38 | 76.7 | 12.6 | 11 | 77.09 | 9.85 | 18 | 70.61 | 19.27 | 10 | 75.3 | 10.54 | p=0.467 |
| Height (m) | 29 | 1.72 | 0.11 | 6 | 1.69 | 0.10 | 16 | 1.71 | 0.13 | 8 | 1.63 | 0.09 | p=0.252 |
| Weight (kg) | 29 | 92.83 | 36.91 | 6 | 85.15 | 30.71 | 13 | 102.29 | 30.23 | 8 | 86.31 | 24.82 | p=0.65 |
| BMI | 26 | 32.05 | 10.92 | 5 | 31.23 | 9.36 | 12 | 36.70 | 14.31 | 8 | 32.25 | 8.20 | p=0.66 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Continuous variables** | **N** | **median** |  | **N** | **median** |  | **N** | **median** |  | **N** | **median** |  | Kruskal-Wallis H test |
| Duration of current ulcer | 41 | 6 |  | 11 | 6 |  | 18 | 11.5 |  | 10 | 14 |  | p-value = 0.3125 |
| Number of wounds | 41 | 1 |  | 11 | 2 |  | 18 | 1 |  | 10 | 2 |  | p-value = 0.9138 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Categorical variables** | **N** | **Percentage** |  | **N** | **Percentage** |  | **N** | **Percentage** |  | **N** | **Percentage** |  | Pearson's chi-squared test |
| Male | 18 | 0.44 |  | 4 | 0.36 |  | 6 | 0.33 |  | 4 | 0.4 |  | p=0.8839 |
| Venous Insufficiency | 33 | 0.80 |  | 11 | 1 |  | 17 | 0.94 |  | 4 | 0.4 |  | p=0.0013 |
| Reduced mobility | 34 | 0.83 |  | 11 | 1 |  | 15 | 0.83 |  | 9 | 0.9 |  | p=0.4968 |

Table A2. HRQoL statistics of EQ-5D-5L, EQVAS and SPVU-5D at baseline and different points of follow-up by healing status

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **EQ-5D-5L** |  | **EQ-VAS** |  | **SPVU-5D** |  |
|  | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) |
| **Baseline** | | | | | | |
| Unhealed | 77 | 0.67 (0.26) | 75 | 65 (17) | 72 | 0.70 (0.17) |
| **1-month** | | | | | | |
| Unhealed | 55 | 0.73 (0.23) | 55 | 69 (16) | 55 | 0.74 (0.18) |
| Healed | 6 | 0.83 (0.12) | 6 | 67 (8) | 5 | 0.88 (0.06) |
| **3-month** | | | | | | |
| Unhealed | 40 | 0.76 (0.17) | 39 | 68 (14) | 40 | 0.74 (0.17) |
| Healed | 14 | 0.90 (0.14) | 15 | 78 (10) | 13 | 0.87 (0.15) |
| **6-month** | | | | | | |
| Unhealed | 24 | 0.81 (0.19) | 24 | 71 (11) | 24 | 0.78 (0.17) |
| Healed | 21 | 0.89 (0.14) | 22 | 76 (12) | 21 | 0.3 (0.04) |

Table A3. Distribution of EQ-5D-5L and SPVU-5D responses in each dimension at baseline

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| EQ-5D-5L |  |  |  |  |  |
| Level/Dimension | mobility | self-care | usual activities | pain/discomfort | anxiety/depression |
| 1 – no problems | 15% | 70% | 35% | 38% | 54% |
| 2 – slight problems | 31% | 15% | 18% | 14% | 20% |
| 3 – moderate problems | 28% | 8% | 25% | 24% | 13% |
| 4 – severe problems | 23% | 3% | 11% | 20% | 6% |
| 5 – extreme problems | 1% | 3% | 9% | 3% | 4% |
| SPVU-5D |  |  |  |  |  |
| Level/Dimension | pain | mobility | mood | smell | social activities |
| 1 – none of the time | 30% | 19% | 51% | 66% | 28% |
| 2 – a bit/some of the time | 43% | 30% | 19% | 25% | 33% |
| 3 – some/most/all of the time | 21% | 25% | 18% | 1% | 36% |
| 4 – most of the time | 3% | 23% | 4% | / | / |
| 5 – all of the time | / | / | 3% | / | / |
| / The dimension does not contain this level. | | | | | |

Table A4. Distribution of EQ-5D-5L and SPVU-5D responses in each dimension at 1-month follow-up\*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| EQ-5D-5L |  |  |  |  |  |
| Level/Dimension | mobility | self-care | usual activities | pain/discomfort | anxiety/depression |
| 1 – no problems | 26% | 74% | 48% | 43% | 59% |
| 2 – slight problems | 26% | 10% | 19% | 19% | 19% |
| 3 – moderate problems | 24% | 10% | 14% | 26% | 12% |
| 4 – severe problems | 21% | 3% | 10% | 9% | 5% |
| 5 – extreme problems | 3% | 2% | 9% | 3% | 0% |
| SPVU-5D |  |  |  |  |  |
| Level/Dimension | pain | mobility | mood | smell | social activities |
| 1 – none of the time | 38% | 28% | 57% | 79% | 41% |
| 2 – a bit/some of the time | 48% | 29% | 17% | 19% | 29% |
| 3 – some/most/all of the time | 9% | 21% | 12% | 2% | 29% |
| 4 – most of the time | 5% | 22% | 7% | / | / |
| 5 – all of the time | / | / | 2% | / | / |
| \*Only unhealed patients (n=58) were included in this analysis  / The dimension does not contain this level. | | | | | |

Table A5. Distribution of EQ-5D-5L and SPVU-5D responses in each dimension at 3-month follow-up\*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| EQ-5D-5L |  |  |  |  |  |
| Level/Dimension | mobility | self-care | usual activities | pain/discomfort | anxiety/depression |
| 1 – no problems | 10% | 76% | 43% | 50% | 57% |
| 2 – slight problems | 33% | 12% | 26% | 33% | 29% |
| 3 – moderate problems | 38% | 10% | 19% | 12% | 7% |
| 4 – severe problems | 14% | 0% | 5% | 2% | 2% |
| 5 – extreme problems | 5% | 2% | 7% | 2% | 0% |
| SPVU-5D |  |  |  |  |  |
| Level/Dimension | pain | mobility | mood | smell | social activities |
| 1 – none of the time | 48% | 12% | 57% | 76% | 33% |
| 2 – a bit/some of the time | 45% | 43% | 26% | 19% | 33% |
| 3 – some/most/all of the time | 5% | 24% | 7% | 5% | 33% |
| 4 – most of the time | 2% | 21% | 2% | / | / |
| 5 – all of the time | / | / | 2% | / | / |
| \*Only unhealed patients (n=42) were included in this analysis  / The dimension does not contain this level. | | | | | |

Table A6. Distribution of EQ-5D-5L and SPVU-5D responses in each dimension at 6-month follow-up\*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| EQ-5D-5L |  |  |  |  |  |
| Level/Dimension | mobility | self-care | usual activities | pain/discomfort | anxiety/depression |
| 1 – no problems | 19% | 73% | 42% | 50% | 62% |
| 2 – slight problems | 38% | 19% | 27% | 38% | 23% |
| 3 – moderate problems | 23% | 0% | 15% | 8% | 8% |
| 4 – severe problems | 12% | 0% | 4% | 0% | 0% |
| 5 – extreme problems | 8% | 8% | 12% | 0% | 0% |
| SPVU-5D |  |  |  |  |  |
| Level/Dimension | pain | mobility | mood | smell | social activities |
| 1 – none of the time | 46% | 23% | 62% | 81% | 31% |
| 2 – a bit/some of the time | 42% | 38% | 27% | 12% | 42% |
| 3 – some/most/all of the time | 8% | 15% | 0% | 4% | 27% |
| 4 – most of the time | 0% | 23% | 4% | / | / |
| /5 – all of the time | / | / | 0% | / | / |
| \*Only unhealed patients (n=26) were included in this analysis  / The dimension does not contain this level. | | | | | |

Table A7. Patient profiles of those completed all three follow-up surveys and those who are lost to follow-up

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Baseline characteristics** | Lost to follow-up (n=37) | | | Completed all three follow-up surveys (n=43) | | |  |
| **Continuous variables** | **N** | **mean** | **SD** | **N** | **mean** | **SD** | t-test |
| Age | 41 | 75.06 | 14.94 | 41 | 75.20 | 13.07 | p=0.9655 |
| Height (m) | 29 | 1.69 | 0.15 | 30 | 1.71 | 0.13 | p=0.4336 |
| Weight (kg) | 28 | 94.19 | 36.57 | 28 | 92.35 | 29.71 | p=0.8369 |
|  |  |  |  |  |  |  |  |
| **Continuous variables** | **N** | **median** |  | **N** | **median** |  | Kruskal-Wallis H test |
| Duration of current ulcer | 37 | 6 |  | 43 | 8 |  | p-value = 0.9144 |
| Number of wounds | 37 | 1 |  | 43 | 2 |  | p-value = 0.3482 |
|  |  |  |  |  |  |  |  |
| **Categorical variables** | **N** | **Percentage** |  | **N** | **Percentage** |  | Pearson's chi-squared test |
| Male | 15 | 0.41 |  | 17 | 0.40 |  | p=1 |
| Venous Insufficiency | 26 | 0.70 |  | 39 | 0.91 |  | p=0.04 |
| Reduced mobility | 32 | 0.86 |  | 37 | 0.86 |  | p=1 |